Tata India Pharma Fund Review: Performance & Strategy
A line graph showing fund performance over laboratory equipment.
Key Highlights
Explore the Tata India Pharma and Healthcare Fund performance, AUM, top holdings, and strategy based on 2026 data. Ideal for long-term investors.
The Tata India Pharma and Healthcare Fund Direct Growth plan has established a strong medium-to-long-term track record by outperforming its benchmark over 3-year and 5-year periods. Managed by Rajat Srivastava, this sector-focused equity fund navigates high-risk terrain through deliberate sector-specific concentration.
Key Numbers and Fund Metrics
- stands at ₹1,565 Cr as of September 17, 2026.
- is recorded at ₹39.1925 on the same date.
- Demonstrated outperformance spans benchmark comparisons over 3-year and 5-year periods.
- Recent 1-year returns remain modest alongside sector-driven market swings.
Portfolio diversification within the healthcare sector remains a core pillar of the fund strategy. Top holdings consist of Sun Pharmaceutical Industries, Healthcare Global Enterprises, and Divi Laboratories.
Investment Horizon and Strategic Outlook
- Suitability targets investors with a long-term horizon.
- Participants must tolerate short-term volatility and inherent sector swings.
- Short-term gain seekers are less aligned with this thematic exposure.
Consistent performance over extended durations positions the fund as a viable thematic option despite high-risk ratings and modest short-term returns. Investors evaluating this vehicle must weigh sector concentration against proven medium-to-long-term resilience.